- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ANAGENICS Aktie jetzt für 0€ handeln | |||||
| Fr | ANAGENICS LIMITED: AN1 - 1H25 Update | 1 | ASX | ||
| Do | ANAGENICS LIMITED: Notice of General Meeting/Proxy Form | 1 | ASX | ||
| Do | ANAGENICS LIMITED: Anagenics - 1H FY25 Half Year Report | 3 | ASX | ||
| Do | ANAGENICS LIMITED: AN1 - Appendix 4D 1H FY2025 | 3 | ASX | ||
| 10.02. | ANAGENICS LIMITED: Update on 2Q25 Activity Report | 1 | ASX | ||
| 04.02. | ANAGENICS LIMITED: Roquefort Therapeutics Announcement | 2 | ASX | ||
| 31.01. | ANAGENICS LIMITED: Q2 F25 Activity Statement and Appendix 4C | 1 | ASX | ||
| 22.01. | ANAGENICS LIMITED: Long Term Suspended Entities | - | ASX | ||
| 10.01. | ANAGENICS LIMITED: Relisting Update | 1 | ASX | ||
| 10.01. | ANAGENICS LIMITED: Proposed issue of securities - AN1 | 1 | ASX | ||
| 03.01. | ANAGENICS LIMITED: Roquefort Therapeutics Announcement and Voluntary Susp | 1 | ASX | ||
| 02.12.24 | ANAGENICS LIMITED: FOS: FOS Capital - Anagenics Restructure | 2 | ASX | ||
| 02.12.24 | ANAGENICS LIMITED: AN1 - Restructure Update | 4 | ASX | ||
| 25.11.24 | ANAGENICS LIMITED: Results of Meeting | - | ASX | ||
| 24.11.24 | ANAGENICS LIMITED: 2024 AGM Presentation 261124 | - | ASX | ||
| 31.10.24 | ANAGENICS LIMITED: Restructuring Update & Resignation of Director | - | ASX | ||
| 31.10.24 | ANAGENICS LIMITED: Q1 F25 Activity Statement and Appendix 4C | - | ASX | ||
| 30.10.24 | ANAGENICS LIMITED: Appendix 3Z - Karen Matthews | - | ASX | ||
| 21.10.24 | ANAGENICS LIMITED: Notice of Annual General Meeting/Proxy Form | 1 | ASX | ||
| 16.10.24 | ANAGENICS LIMITED: Completion of Face Medi Group Sale | 1 | ASX |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 85,02 | -0,21 % | Nach Aus für Wegovy-Kopien: Hims & Hers: Aktie crasht trotz Rekordumsatz zweistellig - FDA sorgt für Panik! | © Foto: Uncredited - Hims & HersHims & Hers hat am Montag eine bullishe Umsatzprognose für das kommende Jahr veröffentlicht, die die Erwartungen der Wall Street übertraf. Dennoch stürzte die Aktie nachbörslich... ► Artikel lesen | |
| AURORA CANNABIS | 4,560 | -0,96 % | UNGLAUBLICHE Sondermeldung bei Aurora Cannabis Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| CANOPY GROWTH | 1,190 | +0,85 % | UNGLAUBLICHE Sondermeldung bei Canopy Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| TILRAY BRANDS | 0,650 | -0,46 % | UNGLAUBLICHE Sondermeldung bei Tilray Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| VERTEX PHARMACEUTICALS | 461,65 | +0,09 % | Vertex Aktie: Strahlende Aussichten entwickeln sich! | Führende Köpfe des Biotechnologieunternehmens Vertex Pharmaceuticals Inc. haben kürzlich Aktien im erheblichen Umfang verkauft. Die Transaktion erfolgte zu einem Zeitpunkt, an dem die Vertex-Aktie eine... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,133 | 0,00 % | TAAT Global Alternatives Inc.: TAAT Announces Late Filing of Annual Financial Statements and Management Cease Trade Order | ||
| CRONOS GROUP | 1,853 | -1,65 % | Cronos Group Inc.: Cronos Group Reports 2024 Fourth Quarter and Full-Year Results | Net revenue in Q4 2024 increased by 27% year-over-year to $30.3 million; Net revenue in FY 2024 increased by 35% year-over-year to $117.6 million Spinach® Ends 2024 as the Number One Cannabis Brand... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN) | le 30 septembre/September 2024
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
| ORGANIGRAM | 1,070 | +4,29 % | ORGANIGRAM HOLDINGS INC. - 6-K, Report of foreign issuer | ||
| IONIS PHARMACEUTICALS | 32,130 | +3,31 % | Ionis Pharmaceuticals, Inc.: Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome | Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design
Bayley-4 expressive communication selected as Phase 3 study primary endpoint
... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,550 | -1,65 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2024 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| MYDECINE INNOVATIONS GROUP | 0,004 | 0,00 % | Mydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial Statements | Mydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial Statements
PR Newswire
LONDON, United Kingdom, November 21
MYDECINE ANNOUNCES FILING OF Q3 FINANCIAL... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 17,106 | -1,84 % | Santhera Pharmaceuticals Holding AG: Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany | Ad hoc announcement pursuant to Art. 53 LR
AGAMREE® is the first product to receive an agreed federal price in Germany for the treatment of all DMD patients 4 years and older, and independent of... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 7,460 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash | Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,469 | +4,13 % | Cassava Sciences, Inc.: Cassava Sciences Reports 2024 Financial Results and Provides Business Update | Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic... ► Artikel lesen |
ANAGENICS LIMITED gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANAGENICS LIMITED finden Sie auf Wallstreet Online.
